Effect of Terminalia arjuna (add-on medication) on Cardiac Function In Patients of Coronary Artery Disease – A Randomized Controlled Clinical Study
DOI:
https://doi.org/10.61841/ygc07s85Keywords:
Coronary artery disease, Terminalia arjuna, Hridya, Ejection fraction, 6MWT, hsCRPAbstract
Background - Coronary artery disease (CAD) is a major cause of death all over globe.
Its incidence is rapidly increasing in developing countries also. Despite significant diagnostic and interventional advancement in cardiovascular area, still it is the most common cause of morbidity and mortality. So there is need of integrated approach & to search a medicine which is cardio protective & Rejuvenating. Terminalia arjuna is described as Hridya(Cardio protective). Objective -This study is planned with the objective to evaluate the effect of Terminalia arjuna on Cardiac function in CAD patients. This drug will be given with the drugs prescribed by the cardiologist as add-on medication. Methodology - It is parallel group, exploratory hospital based study. The patients of Coronary artery disease of age group 40 to 70 years will be screened as per inclusion/exclusion criteria and randomly divided into two groups. One group will be received standard conventional treatment and the other group will be on standard conventional treatment with stem bark of Terminalia arjuna(capsule form). The treatment period will be of 90 days. Patients will be closely followed up throughout the trial period every week for first four weeks and then fortnightly for another eight weeks. Primary outcomes include evaluation of effect of Terminalia arjuna on cardiac function with the help of ejection fraction and 6MWT. Secondary outcomes involve evaluation of vascular inflammatory marker (hsCRP) and lipid profile. Ethics approval was obtained from IEC,DMIMS (DMIMS(DU)/IEC/Aug-2019/8309). The conclusion will be drawn from the results and will be published in peer reviewed journal.
Downloads
References
[1] Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. The Lancet. 1997;349(9063):1436–1442.
[2] Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. The Lancet. 1997;349(9061):1269–1276.
[3] World Health Organization; Geneva: 2005. Preventing Chronic Diseases: A Vital Investment.
[4] Mohan V., Deepa R., Rani S.S. Prevalence of coronary artery disease and its relationship to lipids in a selected population in South India. J Am Coll Cardiol. 2001;38:682–687.
[5] Gupta R., Gupta V.P., Sarna M. Prevalence of coronary heart disease and risk factors in an urban Indian population: Jaipur Heart Watch-2. Indian Heart J. 2002; 54:59–66.
[6] Kamili M.A., Dar I.H., Ali G. Prevalence of coronary heart disease in Kashmiris. Indian Heart J. 2007; 61:44– 49.
[7] Gupta A.K., Bharadwaj A., Ashotra S. Feasibility and training of multipurpose workers in detection, prevention and control of coronary artery disease in apple-belt of Shimla hills. South Asian J Prev Cardiol. 2002; 6:17–22.
[8] Kumar R., Singh M.C., Ahlawat S.K. Urbanization and coronary heart disease: a study of urban–rural differences in northern India. Indian Heart J. 2006; 58:126–130.
[9] Ezzati M., Lopez A.D., Rodgers A. World Health Organization; Geneva: 2004. Comparative quantification of health risks. global and regional burden of disease attributable to major risk factors.
[10] Tyler VM, Premila MS. Ayurvedic Herbs: A Clinical Guide to the Healing Plants of Traditional Indian Medicine.
[11] Maulik SK, Talwar KK. Therapeutic potential of Terminalia arjuna in cardiovascular disorders. Am J Cardiovasc Drugs. 2012;12:157–63.
[12] Bhatia J, Bhattacharya SK, Mahajan P, Dwivedi S. Effect of Terminalia arjuna on coronary flow–an experimental study (Abstract) Indian J Pharmacol. 1998;30:118.
[13] Jain V, Poonia A, Agarwal RP, Panwar RB, Kochar DK, Mishra SN. Effect of Terminalia arjuna in patients of angina pectoris (A clinical trial) Indian Med Gaz. 1992; 36: 56–9.
[14] Dwivedi S, Agarwal MP. Antianginal and cardioprotective effects of Terminaliaarjuna, an indigenous drug, in coronary artery disease. J Assoc Physicians India. 1994;42:287–9.
[15] Dwivedi S, Jauhari R. Beneficial effects of Terminalia arjuna in coronary artery disease. Indian Heart J. 1997;49: 507–10.
[16] Kumar PU, Adhikari P, Pereira P, Bhat P. Safety and efficacy of Hartone in stable angina pectoris–an open comparative trial. J Assoc Physicians India. 1999;47:685–9.
[17] Bharani A, Ganguli A, Mathur LK, Jamra Y, Raman PG. Efficacy of Terminaliaarjuna in chronic stable angina: A double-blind, placebo-controlled, crossover study comparing Terminalia arjuna with isosorbidemononitrate. Indian Heart J. 2002;54:170–5.
[18] Patil RH, Prakash K, Maheshwari VL. Hypolipidemic effect of Terminalia arjuna (L.) in experimentally induced hypercholesteremic rats. Acta Biol Szeged. 2011;55:289–93.
[19] A.BharaniA.GangulyK.D.Bhargava, Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. International Journal of Cardiology.1995;49(3): 191-199
[20] S. Dwivedi ,A. Aggarwal,M.P. Agarwal,S. Rajpal.Role of Terminalia arjuna in ischaemic mitral regurgitati0n, International journal of Cardiology,100(3): 507-508
[21] Baoliang Zhong, How to Calculate Sample Size in Randomized Controlled Trial? Journal of Thoracic Disease. 2009; 1(1)
[22] Mertz DP “Atherosclerosis-index” (LDL/HDL): risk indicator in lipid metabolism disorders. Med. Klin 1980;75: 159–61.
[23] Malaspina JP, Bussière H, Le Calve G The total cholesterol/HDL cholesterol ratio: a suitable atherogenesis index. Atherosclerosis 1981;40: 373–75.
[24] Kayamori F, Igarashi K Effects of dietary nasunin on the serum cholesterol level in rats. Biosci Biotechnol Biochem 1994;58: 570– 71.
[25] Chan et al,Development of short seattle angina questionnaire. Circulation: Cardiovascular Quality and Outcomes.2014;7(5):640-647
[26] Bhatia J, Bhattacharya SK, Mahajan P, Dwivedi S. Effect of Terminalia arjuna on coronary flow–an experimental study (Abstract) Indian J Pharmacol. 1998;30:118.
[27] Verma P, Muneesh, Rani S, Bhutani G. Experimental Evaluation of Terminalia arjuna (Aqueous Extract) on cardiovascular system in comparison to digoxin. J Dent Med Sci. 2013;7:48–51.
[28] Gauthaman K, Maulik M, Kumari R, Manchanda SC, Dinda AK, Maulik SK. Effect of chronic treatment with bark of Terminalia arjuna: A study on the isolated ischemic-reperfused rat heart. J
Ethnopharmacol. 2001;75:197–201
[29] Kumar, G. K., & Prasad, R. S. (2019). A non-linear kernel feature subset selection based semi-supervised framework for medical disease prediction. International Journal of Advanced Science and Technology, 28(17), 517-526. Retrieved from www.scopus.com
[30] Kumar, R., Pruthi, M., & Taneja, G. (2019). Inventory model for deteriorating products with life time and demand depending on price. International Journal of Advanced Science and Technology, 27(1), 48-52.
Retrieved from www.scopus.com
[31] Kumar, S., & Bathla, R. K. (2019). Multimodal approach with face and iris to enhance the efficiency of biometric system using soft biometrics. International Journal of Advanced Science and Technology, 28(16), 1572-1581. Retrieved from www.scopus.com
[32] Lakshmi, P., Bharadwaj, A., & Kumar Srivastava, R. (2019). Microbial profile of bacteriuria in pregnant women and their antibiogram. International Journal of Advanced Science and Technology, 28(14), 337-344.
Retrieved from www.scopus.com
[33] Lee, S. -., Choi, A. -., Kim, S. -., Won, J. -., & Lee, K. -. (2019). Comparison of EMG activity using spectrum indices from biceps femoris muscle during treadmill walking. International Journal of Advanced Science and Technology, 28(3), 33-39. Retrieved from www.scopus.com
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
